COPD combination benefits questioned

Respiratory disease - Research suggests combination therapy does not offer additional benefits in lung disease.

Combination therapy for COPD was thought to give additional benefits
Combination therapy for COPD was thought to give additional benefits

Adding long-acting beta- agonists (LABAs) to corticosteroid therapy for COPD does not appear to offer additional benefits, Dutch research has suggested.

The latest findings go against a recent analysis of the TORCH trial which found that combination therapy could help to reduce COPD exacerbations.

The Dutch study randomly assigned 114 steroid-naive patients or former smokers with moderate to severe COPD to one of four treatment groups.

The groups were given the inhaled corticosteroid (ICS) fluticasone for six months; fluticasone for 30 months; fluticasone in combination with the LABA salmeterol for 30 months; or placebo.

The patients were followed up for two-and-a-half years during which time the researchers noted any symptoms of COPD, performed spirometry and checked adherence to medication by counting the doses in the inhalers.

At the end of the study, the researchers found that treatment with fluticasone had helped to reduce the decline in lung function and improved airway hyper-responsiveness and overall health status.

But combination therapy did not provide further anti-inflammatory effects compared with fluticasone alone. Addition of salmeterol had no incremental effect on bronchial epithelial parameters or sputum inflammatory cells.

Combination therapy did, however, improve the level of FEV1 without further influencing lung function decline.

The researchers, led by Dr Therese Lapperre from Leiden University Medical Centre in Groningen, said that the improvement in the level of FEV1 with combination therapy may be down to a residual bronchodilator effect of salmeterol and not further disease modification.

They concluded: 'ICS decreases inflammation and can attenuate decline in lung function in steroid-naive patients with moderate to severe COPD.

'Adding LABAs does not enhance the effects of ICS therapy.'

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register

Already registered?

Sign in

Follow Us:

Just published

Viewpoint: Why NICE guidance on domestic abuse needs to be updated

Viewpoint: Why NICE guidance on domestic abuse needs to be updated

Dr Vasumathy Sivarajasingam explains why screening for domestic abuse should be standard...

PCNs opt out of phase 2 of COVID-19 vaccination programme over workload pressure

PCNs opt out of phase 2 of COVID-19 vaccination programme over workload pressure

Some PCNs have opted out of phase 2 of the COVID-19 vaccination programme, with others...

UK COVID-19 vaccination programme tracker

UK COVID-19 vaccination programme tracker

GPs across the UK are playing a leading role in the largest-ever NHS vaccination...

CVT risk from COVID-19 infection 'significantly higher' than from vaccines, study suggests

CVT risk from COVID-19 infection 'significantly higher' than from vaccines, study suggests

The risk of cerebral venous thrombosis (CVT) following COVID-19 infection is eight...

‘Warm and kind’ retired Derbyshire GP dies from COVID-19

‘Warm and kind’ retired Derbyshire GP dies from COVID-19

Retired Derbyshire GP Dr Om Prakash Chawla, who was known for his warmth and kindness,...

GPs can learn from pandemic to strengthen relationship with patients, says RCGP chair

GPs can learn from pandemic to strengthen relationship with patients, says RCGP chair

General practice can build on changes to care during the COVID-19 pandemic to strengthen...